Videos

Ghassan K. Abou-Alfa, MD, discusses the data from a phase 3 trial evaluating camrelizumab and rivoceranib vs sorafenib in the first-line for unresectable hepatocellular carcinoma.

Naomi B. Haas, MD, discusses the choice of frontline treatment for favorable-risk patients with advanced clear cell renal cell carcinoma.

Erika P. Hamilton, MD, discusses the wide-ranging impacts of the introduction of fam-trastuzumab deruxtecan-nxki for patients with HER2-positive breast cancer.

Edward B. Garon, MD, MS, discusses the mechanism of action of canakinumab.

Wesley Burkett, MD, discusses the next steps for treating patients with endometrial cancer.

Melina E. Marmarelis, MD, reports the study design of the Chrysalis-2 trial and ongoing trials researching the combination of amivantamab and lazertinib in patients with EGFR-mutated advanced non–small cell lung cancer.

Eytan M. Stein, MD, discusses the unmet needs and challenges for treating patients with acute myeloid leukemia.

Dr Neal outlines second-line targeted treatment selection for the patient case, while Lauren Welch, MSN, NP-C, AOCNP, shares her experience with managing the adverse effects of mobocertinib in patients with EGFR exon 20-mutated mNSCLC and comments on potential strategies for treatment modification.

Dr Piotrowska and Lauren Welch offer insight into results interpretation and subsequent treatment decision-making for patients with mNSCLC who are found to harbor an EGFR exon 20 insertion mutation through biomarker testing.

Martin Dreyling, MD, discusses the outcomes of the phase 3 TRIANGLE study evaluating ibrutinib in patients with mantle cell lymphoma.

Andreas Saltos, MD, discusses the current space for patients with non-small cell lung cancer harbording EGFR and KRAS mutations.

Karen L. Reckamp, MD, discusses the current limitations with standard of care treatment for patients with non–small cell lung cancer.

Rana McKay, MD closes by offering actionable advice for community oncologists and considers the potential clinical implications of these and other emerging data.

Tapan Kadia, MD, discusses the recent and upcoming changes in treatment of acute myeloid leukemia for patients who are not candidates for intensive remission induction therapy.

Joshua Richter, MD, provides insight on the impact of the addition of daratumumab to treatments for patients with multiple myeloma.

Discussion centered around the unmet needs that the COSMIC-313 trial aims to address, as well as information about included patient populations, study design, and recent conference data.

Dr McKay reviews key trial data from the CheckMate 9ER trial including eligible patient populations, study design, and safety/efficacy data.

Marc S. Ernstoff, MD, discusses metastatic melanoma and how patients may be managed.

Shaji Kumar, MD, discusses the incidence and management of infections in patients receiving teclistamab-cqyv or other bispecific agents for relapsed/refractory multiple myeloma.

Michael Chuong, MD, discusses the study design of a trial evaluating radiation therapy in patients with locally advanced pancreatic cancer.

Allan Pickens, MD, discusses the current treatment landscape for esophageal cancer.

Richard Kim, MD, walks through options in the frontline setting for patients with advanced staged hepatocellular carcinoma and how newer treatments have impacted this patient population.

Parminder Singh, MD, discusses the safety associated with standard-of-care tri-modality therapy for muscle-invasive bladder cancer and the addition of atezolizumab to standard of cancer.

Guru P. Sonpavde, MD, provides rationale for the phase 3b STRONG study, and discusses the early data.

Jimmy Caudell, MD, PhD, discusses the overall incidence of human papillomavirus-positive and negative oropharyngeal cancers in the United States.

David W. Dougherty, MD, MBA, discusses telemedicine in oncology after emergence of COVID-19.

Dr Shiller emphasizes the heterogeneity between the various EGFR exon 20 mutations seen in patients with NSCLC, and describes strategies for effectively communicating actionable information about a patient’s mutation status to the clinicians receiving the reports.

Dr Shaji Kumar outlines advice for community oncologists and discusses unmet needs for treating patients with R/R multiple myeloma.

Dr Kumar shares his perspective on the impact of management and monitoring strategies used to minimize the risk of adverse events in patients treated with teclistamab and other bispecifics.

Dr Shaji Kumar highlights bispecifics under development and how BCMA-targeting therapies impact patient selection for the treatment of R/R multiple myeloma.